儿茶酚胺（CAs）及其代谢物是多种疾病重要的生物标志物。由于其体内丰度极低，所以检测前需进行富集纯化以降低基质干扰。其中硼亲和（BAC）萃取技术具有良好的应用前景。然而目前用于CAs萃取的BAC材料均需在碱性条件下完成吸附，易导致CAs的氧化分解；此外其苯硼酸骨架使吸附特异性受到疏水和π-π相互作用的影响。.为解决上述问题，本项目结合BAC和金属氧化物亲和色谱（MOAC）技术，通过制备硼酸杂化氧化锆/铈，实现在中性或弱酸性条件下对CAs及其顺式二醇类代谢物的亲和纯化。新萃取介质的硼酸功能基团表现更高的电负性，与亦能用于萃取顺式二醇的MOAC机理协同作用，可在低pH值环境下吸附CAs，防止其氧化分解；同时材料的全无机骨架避免了疏水及π-π相互作用的干扰，提高萃取选择性。基于该策略，拟建立针对12种CAs及其顺式二醇类代谢物的质谱定量方法，以讨论该类物质体内浓度与精神分裂症间的相关性。

Catecholamines (CAs) and the related metabolites are important neurotransmitters and hormones in vivo, which have been regarded as crucial biomarkers for diagnosis and prognosis of multiple diseases. However, because of the multiplicity and the substoichiometric nature, the direct MS analysis of these targets always shows poor sensitivity. Consequently, proper sample pretreatments are highly required for eliminating the matrix effect before detection. In this aspect, benefiting from the ability of recognizing cis-diol structure in CAs, boronate affinity chromatography (BAC) attracts significant attention. However, the basic working condition (pH 8.5 or higher) could raise the risk of decomposition of CAs and decrease the extracting recovery. Moreover, the commonly used organic BAC materials (based on aromatic boronic acid groups) possess hydrophobic and aromatic π-π interaction properties (deriving from the organic skeleton), which could compromise the selectivity and cause undesirable interferences. .For improvement, the proposed project intends to introduce inorganic BAC and metal oxide affinity chromatography (MOAC) into the pretreatment of CAs and the related cis-diol-containing metabolites. By utilizing borated zirconium oxide or borated cerium oxide as extracting media, we could realize the specific enrichment of those targets under neutral or weak acidic environment. Afterwards, a sensitive UPLC-MS/MS quantification strategy could be carried out for 12 endogenous CAs and the related cis-diol containing metabolites from human plasma. By meta-analysis of the clinical samples, we expect to provide some new insights for the relationship between CAs and schizophrenia.